The study found the candidate elicits “robust antibody responses” and is well-tolerated, the company said Tuesday.
Image: Novavax is advancing a Covid-19 vaccine candidate through clinical trials. COURTESY NOVAVAX
{iframe}https://www.bizjournals.com/washington/news/2020/08/04/novavax-reports-positive-phase-1-data-on-its-covid.html{/iframe}